Form 4: Director Otis Brawley Receives Equity Grant at Lyell

Lyell Immunopharma director Otis Brawley was granted 9,250 stock options as part of standard director compensation.

Summary

• Director Otis Brawley acquired 9,250 stock options in Lyell Immunopharma, Inc. (LYEL).
• The options have an exercise price of $13.22 per share.
• The grant date for the options is June 10, 2026, with an expiration date of June 9, 2036.
• The reporting person holds 1,782 shares of common stock following the transaction.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing reflecting standard director compensation practices.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• None identified; this is a standard compensatory filing.

Risks

• The value of the granted options is subject to market volatility and the future performance of Lyell Immunopharma's common stock.

Future Outlook

The options vest on the earlier of the next annual stockholders' meeting following June 10, 2026, or the first anniversary of the grant date, contingent upon continued service.

Industry Context

StockSavvy.ai notes that equity grants for independent directors are standard practice in the biotechnology sector to ensure board alignment with corporate performance and retention of key expertise.

Comparison to Industry Standards

• The grant structure is consistent with standard equity compensation packages for non-employee directors in mid-cap biotech firms.

Stakeholder Impact

• Minimal impact on shareholders; represents standard director incentive alignment.

Next Steps

• Vesting of options upon the earlier of the next annual meeting or June 10, 2027.

Key Dates

Keywords

Lyell Immunopharma, LYEL, Form 4, Insider Trading, Stock Options, Director Compensation